Squarepoint
JNCE

Squarepoint’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Squarepoint’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-35,606
Closed -$39.5K – 3985
2022
Q4 		$39.5K Buy
+35,606
New +$50.7K ﹤0.01% 3073
2022
Q1 		– Sell
-11,054
Closed -$92K – 3766
2021
Q4 		$92K Sell
11,054
-2,888
-21% -$23.8K ﹤0.01% 2937
2021
Q3 		$104K Sell
13,942
-50,023
-78% -$310K ﹤0.01% 2659
2021
Q2 		$435K Buy
63,965
+51,891
+430% +$431K ﹤0.01% 2246
2021
Q1 		$124K Sell
12,074
-73,860
-86% -$809K ﹤0.01% 2853
2020
Q4 		$602K Buy
85,934
+53,997
+169% +$420K ﹤0.01% 1672
2020
Q3 		$261K Buy
+31,937
New +$198K ﹤0.01% 1921
2019
Q1 		– Sell
-76,457
Closed -$258K – 2526
2018
Q4 		$258K Buy
76,457
+53,948
+240% +$252K ﹤0.01% 1566
2018
Q3 		$146K Buy
+22,509
New +$167K ﹤0.01% 1836

Other funds holding JNCE

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACM
Ardent Capital Management Cincinnati, Ohio $241M AUM 23.63% 1-Year Est. Return

Squarepoint's JNCE Position: Q1 2023 in Review

Squarepoint sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2023, closing a stake of 35,606 shares — an estimated $39.5K sold.

Squarepoint first reported a position in JNCE in Q3 2018 and held it in 9 quarters. The position peaked at $602K in Q4 2020. 84 funds tracked by Wall St. Rank hold JNCE as of Q1 2023.

  • Squarepoint reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Squarepoint sold 35,606 Jounce Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $39.5K.
  • Squarepoint first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2018 and held it in 9 quarters.
  • Squarepoint's Jounce Therapeutics, Inc. Common Stock position peaked at $602K in Q4 2020.
  • 84 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Squarepoint's 13F filing for Q1 2023, filed 15 May 2023.